Dosing of LT4 in Older Individuals
Key facts
- Where
- Philadelphia, United StatesSee the site
- Phase
- Phase 4
Where in United States
- Penn Medicine, Smilow Translational Research CenterPhiladelphia, United StatesContact: Anne R. Cappola, M.D., Sc.M.Taking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- University of Pennsylvania
- Trial code
- NCT06073665
- Record updated
- 19 February 2026
- Original description
Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.Read full original descriptionShow less
Levothyroxine Dosing in Older Individuals
Our overall goal is to determine the clinical consequences of allowing greater flexibility in LT4 dosing in older individuals who take LT4.
Inclusion: Provision of signed and dated informed consent form; Stated willingness to comply with all study procedures and availability for the duration of the study; Male or female, community dwelling, aged 65 years or older; Diagnosed with hypothyroidism of any etiology for at least 6 months, taking 75-200 mcg per day LT4 and a minimum of 1.2 mcg/kg/day with no dose adjustment since the last TSH test; Ability to take oral medication and be willing to adhere to the medication regimen; Adherence to lifestyle considerations.
Exclusion: Current use of liothyronine (LT3), thyroid extracts, Tirosint liquid or capsules, and medications that interfere with thyroid function or thyroid function tests; Currently taking multikinase or checkpoint inhibitor therapy; History of thyroid cancer requiring suppression of TSH secretion; Other conditions which, in the opinion of the investigators, would prevent them from participating in the full duration of the study; Any history of food dye allergy; GFR <30 ml/min/1.73 m2 within the prior 12 months; Hypopituitarism; Unable to understand and comply with study requirements, as assessed by study staff and the PI, will be excluded.